Skip to page content
Back to overview

Jul 23, 2019

Immunotherapy for Chronic Liver Diseases

Life Sciences, Infectious Diseases

  • Novel vaccination strategy against chronic liver diseases through stimulation of IMATEs with TLR9-L
  • IMATEs are an anatomic compartment within the liver tissue consisting of myeloid cells
  • iMATEs overcome regulatory cues that limit immune response during chronic liver infections

Your contact

Dr. Katharina Stoiber

E-Mail:
kstoiber@baypat.de
Phone:
+49 (0) 89 5480177 - 40
Reference Number:
B72272

Challenge

Immunotherapy of chronic hepatitis B is particularly difficult as the hepatic microenvironment is limiting local cytotoxic T lymphocyte (CTL) proliferation after infection. However, CTLs are an important element for overcoming chronic infections of the liver. So far only a prophylactic vaccination against hepatitis B virus is available and a protection post-infection by means of vaccination has not been possible to this point. Accordingly, there is a strong demand for new therapeutic options.

Innovation

A so far unrecognized anatomic compartment within the liver tissue consisting of myeloid cells - called iMATEs (“intrahepatic myeloid-cell aggregates for T cell population expansion”) - can be exploited as a novel vaccination strategy against chronic viral liver infections. iMATEs overcome regulatory cues that limit immune response during chronic liver infections and support local CTL expansion by generation of cocoon-like structures. A dramatic expansion of CTLs in the liver can be achieved by targeted stimulation of iMATEs with TLR9-L as a prophylactic or therapeutic vaccine. The proof-of concept has been shown in vivo in mouse models.

Commercial Opportunities

The present invention provides a convenient and reliable prophylactic as well as therapeutic vaccine strategy. The use of TLR9 agonists induces the formation of iMATEs, which generate a sufficient number of CTLs resulting in the overcoming of chronic viral infections.

Further advantages and opportunities:

  • use as prime - jump strategy for enhancement of CTLs
  • entities of CTLs are increased at least 5 fold in peripheral organs (e.g. liver)
  • use as a prophylactic or therapeutic vaccine against infections with an intracellular pathogen
  • readily available as a kit, containing a prime agent and a multiplying jump agent

Development Status

Proof of concept in vivo.

References

    • Knolle, P.A., Böttcher, J. & Huang, L. The role of hepatic immune regulation in systemic immunity to viral ­ infection. Med Microbiol Immunol. 204, 21 (2015).
    • Hunag, L.R., et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection. Nat. Immunol. 14, 574–583 (2013).
    • Protzer, U., Maini, M.K. & Knolle, P.A. Living in the liver: hepatic infections. Nat. Rev. Immunol. 12, 201–213 (2012).

Interested? Get in touch!

Contact a specific team member via the Team section or simply use our contact form for your request.

Privacy settings

This website uses cookies. Cookies improve its usage and help make this website better.
Privacy Policy